1# Library to Find Best eBook for Read
Author : Magdalene K. Montgomery
Release : 2022-09-07
Genre : Medical
Kind : eBook
Book Rating : 135/5 ( reviews)
Book Synopsis Non-Alcoholic Steatohepatitis (NASH) – Metabolic Contributors and Therapeutic Targets by : Magdalene K. Montgomery
Download or read book Non-Alcoholic Steatohepatitis (NASH) – Metabolic Contributors and Therapeutic Targets written by Magdalene K. Montgomery. This book was released on 2022-09-07. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Ana Blas-García
Release : 2022-12-05
Genre : Science
Kind : eBook
Book Rating : 588/5 ( reviews)
Book Synopsis Advances in Non-Alcoholic Fatty Liver Disease Therapeutics: Pathogenic Mechanisms and Targets by : Ana Blas-García
Download or read book Advances in Non-Alcoholic Fatty Liver Disease Therapeutics: Pathogenic Mechanisms and Targets written by Ana Blas-García. This book was released on 2022-12-05. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Andrew J. Krentz
Release : 2019-04-02
Genre : Medical
Kind : eBook
Book Rating : 480/5 ( reviews)
Book Synopsis Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease by : Andrew J. Krentz
Download or read book Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease written by Andrew J. Krentz. This book was released on 2019-04-02. Available in PDF, EPUB and Kindle. Book excerpt: This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
Author : Malcolm G. Parker
Release : 1991
Genre : Science
Kind : eBook
Book Rating : /5 ( reviews)
Book Synopsis Nuclear Hormone Receptors by : Malcolm G. Parker
Download or read book Nuclear Hormone Receptors written by Malcolm G. Parker. This book was released on 1991. Available in PDF, EPUB and Kindle. Book excerpt: An overview of the supergene family made up of those nuclear hormone receptors which recognize thyroid and steroid hormones, vitamen D and retinoic acid and which are characterized by their ability to bind both ligands and the genes which respond to them.
Author : Ronit Shiri-Sverdlov
Release : 2022-01-28
Genre : Science
Kind : eBook
Book Rating : 783/5 ( reviews)
Book Synopsis NASH and Systemic Complications by : Ronit Shiri-Sverdlov
Download or read book NASH and Systemic Complications written by Ronit Shiri-Sverdlov. This book was released on 2022-01-28. Available in PDF, EPUB and Kindle. Book excerpt: Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH). NASH is a chronic inflammatory condition of the liver that can further progress to fibrosis and cirrhosis, which may eventually lead to liver failure and death. While we have increased our mechanistic knowledge regarding the pathogenesis of NASH within the last decade, treatment options are still limited and liver biopsies have remained the gold standard for diagnosis. To achieve major clinical breakthroughs for NASH patients, it is not sufficient to use a single animal model, since each model has specific limitations. Furthermore, we should rely more on alternative models such as organ-on-a-chip, which will enable us to explore unknown aspects of disease pathogenesis much faster and serve as clinically relevant surrogates for murine models. Another important direction for the improvement of patient health is to pay more attention to extrahepatic, organ-specific and systemic effects, which are associated with NASH. The articles in this Special Issue include an up-to-date overview of the rapidly developing technologies, novel targets for intervention and insights in the field in NASH. Additionally, these articles describe the major challenges in the field, strategies to overcome them and suggestions for future directions. To improve patient's outcome, clinicians, as well as scientists with biomedical, nutrition, physics and mathematics backgrounds, should join forces. Although challenges remain, the future of the field seems promising as these novel technologies and developments are expected to lead to progress in NASH.
